3.17 References 總表 指引（Guidelines） 2025 AHA/ACC Guideline for High Blood Pressure (Circulation) 2025 AHA/ACC Guideline (PubMed) 2025 AHA Professional Hub 2024 ESC Guidelines for Elevated BP and HTN (Eur Heart J) 2024 ESC Guidelines (ESC Official) 2023 ESH Guidelines (Journal of Hypertension) 2023 ESH Guidelines (ESH Official) 2022 Taiwan TSOC/THS Guidelines (PMC) 2022 Taiwan Guidelines PDF (TSOC) KDIGO 2021 BP in CKD (Kidney International) KDIGO BP in CKD (Official Page) Landmark RCTs SPRINT (NEJM 2015) SPRINT Final Report (NEJM 2021) STEP Trial (NEJM 2021) PATHWAY-2 (Lancet 2015) PATHWAY-2 mechanisms (PMC) PARADIGM-HF (NEJM 2014) EMPA-REG OUTCOME (NEJM 2015) EMPEROR-Reduced (NEJM 2020) FIDELIO-DKD (NEJM 2020) FIGARO-DKD (NEJM 2021) CHAP Trial (NEJM 2022) INTERACT-3 (Lancet 2023) Renal Denervation Medtronic Symplicity Spyral FDA Approval SCAI: RDN Systems FDA Approval Summary TCTMD: Symplicity Spyral Approved 台灣藥物資料查詢 食藥署西藥許可證查詢 中央健保署藥品代碼查詢 ⚠️ 免責聲明：本整理為臨床知識複習用途，實際處方需依個別病人狀況、共病、藥物交互作用與最新指引調整，並由醫師判斷。商品名與健保給付狀態以衛福部食藥署許可證與健保署公告為準。